Exact Mass: 690.3662164000001

Exact Mass Matches: 690.3662164000001

Found 215 metabolites which its exact mass value is equals to given mass value 690.3662164000001, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dalfopristin

(6R,10R,11R,12Z,17Z,19Z,21S)-6-[2-(Diethylamino)ethanesulphonyl]-14,21-dihydroxy-11,19-dimethyl-10-(propan-2-yl)-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.0³,⁷]octacosa-1(27),12,14,17,19,25(28)-hexaene-2,8,23-trione

C34H50N4O9S (690.3298330000001)


Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D025361 - Streptogramins

   
   

PGP(i-12:0/i-12:0)

[(2S)-3-({[(2R)-2,3-bis[(10-methylundecanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C30H60O13P2 (690.350897)


PGP(i-12:0/i-12:0) is a phosphatidylglycerophosphate (PGP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site followed by another phosphate moiety. Phosphatidylglycerolphosphate is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant (up to 11\\% of the total). It is well established that the concentration of phosphatidylglycerolphosphate increases during fetal development. Phosphatidylglycerolphosphate may be present in animal tissues merely as a precursor for cardiolipin synthesis. As is the case with diacylglycerols, phosphatidylglycerophosphates can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PGP(i-12:0/i-12:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. They are synthesized by the addition of glycerol 3-phosphate to a CDP-diacylglycerol. In turn, PGPs are dephosphorylated to phosphatidylglycerols (PGs). While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes.

   

PA(12:0/PGF2alpha)

[(2R)-2-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}-3-(dodecanoyloxy)propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(12:0/PGF2alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/PGF2alpha), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGF2alpha/12:0)

[(2R)-3-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}-2-(dodecanoyloxy)propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(PGF2alpha/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF2alpha/12:0), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/PGE1)

[(2R)-3-(dodecanoyloxy)-2-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(12:0/PGE1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/PGE1), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE1/12:0)

[(2R)-2-(dodecanoyloxy)-3-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(PGE1/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE1/12:0), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/PGD1)

[(2R)-3-(dodecanoyloxy)-2-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(12:0/PGD1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/PGD1), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD1/12:0)

[(2R)-2-(dodecanoyloxy)-3-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(PGD1/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD1/12:0), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/5-iso PGF2VI)

[(2R)-2-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(14:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/5-iso PGF2VI), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(5-iso PGF2VI/14:0)

[(2R)-3-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(5-iso PGF2VI/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/14:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/PGF2alpha)

[(2R)-2-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(i-12:0/PGF2alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/PGF2alpha), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGF2alpha/i-12:0)

[(2R)-3-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(PGF2alpha/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF2alpha/i-12:0), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/PGE1)

[(2R)-2-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(i-12:0/PGE1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/PGE1), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE1/i-12:0)

[(2R)-3-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(PGE1/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE1/i-12:0), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/PGD1)

[(2R)-2-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(i-12:0/PGD1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/PGD1), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD1/i-12:0)

[(2R)-3-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(PGD1/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD1/i-12:0), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/5-iso PGF2VI)

[(2R)-2-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(i-14:0/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/5-iso PGF2VI), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(5-iso PGF2VI/i-14:0)

[(2R)-3-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C35H63O11P (690.4107778)


PA(5-iso PGF2VI/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(5-iso PGF2VI/i-14:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   
   
   
   
   
   

Fumonisin La4

Fumonisin La4

C34H58O14 (690.3826368)


CONFIDENCE isolated standard

   

Hederagenin base -2H + 1O, O-AcetylHex

Hederagenin base -2H + 1O, O-AcetylHex

C38H58O11 (690.3978918)


Annotation level-3

   
   
   

3-alpha-trans-sinapoyloxyjhanol 18-O-beta-D-glucopyranoside

3-alpha-trans-sinapoyloxyjhanol 18-O-beta-D-glucopyranoside

C37H54O12 (690.3615084)


   
   
   

23-O-acetyl-7,8-didehydroshengmanol 3-O-beta-D-galactopyranoside

23-O-acetyl-7,8-didehydroshengmanol 3-O-beta-D-galactopyranoside

C38H58O11 (690.3978918)


   
   

furost-25(27)-ene-1beta,2beta,3beta,4beta,5beta,6beta,7alpha,22,26-nonaol 26-O-beta-D-glucopyranoside

furost-25(27)-ene-1beta,2beta,3beta,4beta,5beta,6beta,7alpha,22,26-nonaol 26-O-beta-D-glucopyranoside

C33H54O15 (690.3462534)


   

3beta-O-(6-O-methyl-beta-D-glucuronopyranosyl)-olean-12-ene-28,29-dioic acid 29-methyl ester|coryternic acid 3-O-beta-D-glucuronopyranoside 6-O-methyl ester

3beta-O-(6-O-methyl-beta-D-glucuronopyranosyl)-olean-12-ene-28,29-dioic acid 29-methyl ester|coryternic acid 3-O-beta-D-glucuronopyranoside 6-O-methyl ester

C38H58O11 (690.3978918)


   

7,8,16,17-tetrahydro-23R,24R-O-acetylhydroshengmanol-3-O-beta-D-galactopyranoside

7,8,16,17-tetrahydro-23R,24R-O-acetylhydroshengmanol-3-O-beta-D-galactopyranoside

C38H58O11 (690.3978918)


   

3alpha-trans-feruloyloxy-2alpha-O-acetylurs-12-en-28-oic acid

3alpha-trans-feruloyloxy-2alpha-O-acetylurs-12-en-28-oic acid

C42H58O8 (690.4131468)


   

cucurbitacin F 16-O-(2?-O-acetyl-4?,6?-dideoxy-alpha-allopyranoside)|datiscoside J

cucurbitacin F 16-O-(2?-O-acetyl-4?,6?-dideoxy-alpha-allopyranoside)|datiscoside J

C38H58O11 (690.3978918)


   
   

19-[(1S,4R)-4-hydroxy-1-methoxy-2-oxopentyl]geldanamycin

19-[(1S,4R)-4-hydroxy-1-methoxy-2-oxopentyl]geldanamycin

C35H50N2O12 (690.336358)


   
   
   
   

Cloversaponin II methyl ester

Cloversaponin II methyl ester

C38H58O11 (690.3978918)


   
   
   
   

12-acetoxybeyer-15-ene-18-carboxy beta-glucopyranoside pentaacetate

12-acetoxybeyer-15-ene-18-carboxy beta-glucopyranoside pentaacetate

C36H50O13 (690.3251250000001)


   
   
   

26-O-beta-D-glucopyranosyl furost-5-en-1beta,3beta,22zeta-triol 1-sulphate

26-O-beta-D-glucopyranosyl furost-5-en-1beta,3beta,22zeta-triol 1-sulphate

C33H54O13S (690.3284954000001)


   

(4R,9beta,16alpha,24S)-20-hydroxy-25-methoxy-9,10,14-trimethyl-1,11,22-trioxo-16,24-epoxy-4,9-cyclo-9,10-secocholesta-2,5-dien-2-yl beta-D-glucopyranoside|16alpha,24alpha-epoxy-2,20beta-dihydroxy-25-methoxy-3,11,22-trioxo-cucurbita-1,5-diene 2-O-beta-D-glucopyranoside|colocynthin A

(4R,9beta,16alpha,24S)-20-hydroxy-25-methoxy-9,10,14-trimethyl-1,11,22-trioxo-16,24-epoxy-4,9-cyclo-9,10-secocholesta-2,5-dien-2-yl beta-D-glucopyranoside|16alpha,24alpha-epoxy-2,20beta-dihydroxy-25-methoxy-3,11,22-trioxo-cucurbita-1,5-diene 2-O-beta-D-glucopyranoside|colocynthin A

C37H54O12 (690.3615084)


   

6-[4-(4-carboxy-3-hydroxy-5-methylphenoxy)carbonyl-3-hydroxy-5-pentadecylphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

NCGC00386053-01!6-[4-(4-carboxy-3-hydroxy-5-methylphenoxy)carbonyl-3-hydroxy-5-pentadecylphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H50O13 (690.3251250000001)


   

2,2-BI-9H-FLUORENE, 9,9,9,9-TETRAKIS(4-METHYLPHENYL)-

2,2-BI-9H-FLUORENE, 9,9,9,9-TETRAKIS(4-METHYLPHENYL)-

C54H42 (690.3286332)


   

3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-carboxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid

3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-carboxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid

C30H58O17 (690.3673818)


   
   
   

DALFOPRISTIN

DALFOPRISTIN

C34H50N4O9S (690.3298330000001)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D025361 - Streptogramins C254 - Anti-Infective Agent > C258 - Antibiotic

   

Hederagenin base-2H + 1O, O-AcetylHex

Hederagenin base-2H + 1O, O-AcetylHex

C38H58O11 (690.3978918)


   

6-[4-(4-Carboxy-3-hydroxy-5-methylphenoxy)carbonyl-3-hydroxy-5-pentadecylphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

6-[4-(4-Carboxy-3-hydroxy-5-methylphenoxy)carbonyl-3-hydroxy-5-pentadecylphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H50O13 (690.3251250000001)


   

17-(4-Hydroxyphenyl)heptadecanoyl adenylate

17-(4-Hydroxyphenyl)heptadecanoyl adenylate

C33H49N5O9P- (690.3267734)


   
   
   
   
   
   
   
   
   
   
   
   
   

PA(14:0/5-iso PGF2VI)

PA(14:0/5-iso PGF2VI)

C35H63O11P (690.4107778)


   

PA(5-iso PGF2VI/14:0)

PA(5-iso PGF2VI/14:0)

C35H63O11P (690.4107778)


   

PA(i-14:0/5-iso PGF2VI)

PA(i-14:0/5-iso PGF2VI)

C35H63O11P (690.4107778)


   

PA(5-iso PGF2VI/i-14:0)

PA(5-iso PGF2VI/i-14:0)

C35H63O11P (690.4107778)


   

1-[(3S,9S,10R)-9-[[cyclohexylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-[4-(trifluoromethyl)phenyl]urea

1-[(3S,9S,10R)-9-[[cyclohexylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-[4-(trifluoromethyl)phenyl]urea

C37H53F3N4O5 (690.3967843999999)


   

1-cyclohexyl-3-[(3R,9S,10S)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

1-cyclohexyl-3-[(3R,9S,10S)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C36H52Cl2N4O5 (690.3314561999999)


   

1-[(3R,9S,10S)-9-[[cyclohexylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-[4-(trifluoromethyl)phenyl]urea

1-[(3R,9S,10S)-9-[[cyclohexylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-[4-(trifluoromethyl)phenyl]urea

C37H53F3N4O5 (690.3967843999999)


   

N-(2-aminophenyl)-N-[(2R,3R)-2-[[[(4-fluoroanilino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]heptanediamide

N-(2-aminophenyl)-N-[(2R,3R)-2-[[[(4-fluoroanilino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]heptanediamide

C37H47FN6O6 (690.3540934)


   

4-(dimethylamino)-N-[[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-[(4-methoxyphenyl)sulfonylamino]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

4-(dimethylamino)-N-[[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-[(4-methoxyphenyl)sulfonylamino]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C35H54N4O8S (690.3662164000001)


   

1-[(3S,9S,10R)-9-[[cyclohexylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-[4-(trifluoromethyl)phenyl]urea

1-[(3S,9S,10R)-9-[[cyclohexylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-[4-(trifluoromethyl)phenyl]urea

C37H53F3N4O5 (690.3967843999999)


   

1-cyclohexyl-3-[(3S,9S,10S)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

1-cyclohexyl-3-[(3S,9S,10S)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C36H52Cl2N4O5 (690.3314561999999)


   

1-cyclohexyl-3-[(3R,9R,10R)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

1-cyclohexyl-3-[(3R,9R,10R)-9-[[(3,4-dichlorophenyl)methyl-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]urea

C36H52Cl2N4O5 (690.3314561999999)


   

2-[[(2R)-2-[(E)-7-carboxy-5-oxohept-6-enoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[(2R)-2-[(E)-7-carboxy-5-oxohept-6-enoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H61NO11P+ (690.3982026)


   
   
   
   
   
   
   

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[1-acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C33H54O15 (690.3462534)


   

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

[1-hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C33H55O13P (690.3380109999999)


   

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C33H55O13P (690.3380109999999)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C33H55O13P (690.3380109999999)


   

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C33H55O13P (690.3380109999999)


   

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H61NO8P+ (690.4134576)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

(1s,2s,4r,6s,9r,10r,11r,14r,15r)-9-hydroxy-6-(2-methoxypropan-2-yl)-2,9,11,14,19,19-hexamethyl-17-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[12.8.0.0²,¹¹.0⁴,¹⁰.0¹⁵,²⁰]docosa-16,20-diene-8,13,18-trione

(1s,2s,4r,6s,9r,10r,11r,14r,15r)-9-hydroxy-6-(2-methoxypropan-2-yl)-2,9,11,14,19,19-hexamethyl-17-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[12.8.0.0²,¹¹.0⁴,¹⁰.0¹⁵,²⁰]docosa-16,20-diene-8,13,18-trione

C37H54O12 (690.3615084)


   

methyl (1r,9r,10s,12s,13z,18r)-13-ethylidene-4-[(8r,13z,14s,16s,17r,18s)-13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-17-yl]-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

methyl (1r,9r,10s,12s,13z,18r)-13-ethylidene-4-[(8r,13z,14s,16s,17r,18s)-13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-17-yl]-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

7,9,13-trimethyl-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6,14,15,16,17,18,19,20-octol

7,9,13-trimethyl-6-[3-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6,14,15,16,17,18,19,20-octol

C33H54O15 (690.3462534)


   

2-({[2-(7-carboxyheptyl)-6-hydroxy-10-methoxy-9-methyl-3-oxo-1,4,8-trioxaspiro[4.5]decan-7-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

2-({[2-(7-carboxyheptyl)-6-hydroxy-10-methoxy-9-methyl-3-oxo-1,4,8-trioxaspiro[4.5]decan-7-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C37H54O12 (690.3615084)


   

methyl 15-ethylidene-10-[15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl 15-ethylidene-10-[15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

(3as,8as)-7-[(3as,8as)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-3a-[(3as,8as)-3a-[(3as,8as)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-7-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indole

(3as,8as)-7-[(3as,8as)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-3a-[(3as,8as)-3a-[(3as,8as)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-7-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indole

C44H50N8 (690.4158219999999)


   

methyl (1s,4s,5r,6s,7r,8s,10s,14s,15s,16r,18s,19r,22r,23r,25s,26s)-7,14,25-trihydroxy-12-isopropyl-4-methoxy-6,16,22-trimethyl-23-{[(2e)-2-methylbut-2-enoyl]oxy}-3,9,11,17,20-pentaoxaoctacyclo[17.6.1.1⁸,¹⁵.0¹,⁵.0⁶,¹⁸.0⁷,¹⁶.0¹⁰,¹⁴.0²²,²⁶]heptacos-12-ene-4-carboxylate

methyl (1s,4s,5r,6s,7r,8s,10s,14s,15s,16r,18s,19r,22r,23r,25s,26s)-7,14,25-trihydroxy-12-isopropyl-4-methoxy-6,16,22-trimethyl-23-{[(2e)-2-methylbut-2-enoyl]oxy}-3,9,11,17,20-pentaoxaoctacyclo[17.6.1.1⁸,¹⁵.0¹,⁵.0⁶,¹⁸.0⁷,¹⁶.0¹⁰,¹⁴.0²²,²⁶]heptacos-12-ene-4-carboxylate

C36H50O13 (690.3251250000001)


   

(2s,3r,4s,5r,6r)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl (1r,4s,5r,9s,10r,13r,15r)-15-(acetyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

(2s,3r,4s,5r,6r)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl (1r,4s,5r,9s,10r,13r,15r)-15-(acetyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C36H50O13 (690.3251250000001)


   

5-hydroxy-7-[5-hydroxy-2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxopyrano[3,2-g]chromen-3-yl]-8,8-dimethyl-3,10-bis(2-methylbut-3-en-2-yl)pyrano[3,2-g]chromen-2-one

5-hydroxy-7-[5-hydroxy-2,2-dimethyl-10-(2-methylbut-3-en-2-yl)-8-oxopyrano[3,2-g]chromen-3-yl]-8,8-dimethyl-3,10-bis(2-methylbut-3-en-2-yl)pyrano[3,2-g]chromen-2-one

C43H46O8 (690.3192516)


   
   

methyl (1r,9r,10s,12r,13e,18r)-13-ethylidene-4-[(8r,13e,14s,16s,17r,18s)-13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-17-yl]-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

methyl (1r,9r,10s,12r,13e,18r)-13-ethylidene-4-[(8r,13e,14s,16s,17r,18s)-13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-17-yl]-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

(3ar,8ar)-7-[(3ar,8ar)-7-[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-3a-[(3as,8as)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indole

(3ar,8ar)-7-[(3ar,8ar)-7-[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-3a-[(3as,8as)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indole

C44H50N8 (690.4158219999999)


   

(1s,4r,9r,10r,11r,12s,13z,16r)-11-hydroxy-13-{2-[(1s,4r,9r,10r,11r,12s,13z,16r)-11-hydroxy-5,5,9-trimethyl-14,18-dioxo-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecan-13-ylidene]ethylidene}-5,5,9-trimethyl-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecane-14,18-dione

(1s,4r,9r,10r,11r,12s,13z,16r)-11-hydroxy-13-{2-[(1s,4r,9r,10r,11r,12s,13z,16r)-11-hydroxy-5,5,9-trimethyl-14,18-dioxo-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecan-13-ylidene]ethylidene}-5,5,9-trimethyl-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecane-14,18-dione

C40H50O10 (690.34038)


   

19'(s)-hydroxyervahanine a

NA

C42H50N4O5 (690.3781009999999)


{"Ingredient_id": "HBIN002223","Ingredient_name": "19'(s)-hydroxyervahanine a","Alias": "NA","Ingredient_formula": "C42H50N4O5","Ingredient_Smile": "CC=C1CN(C2CC3=C(C(CC1C2C(=O)OC)C4=CC5=C(C=C4)C6=C(N5)C7(CC8CC(C7N(C8)CC6)C(C)O)C(=O)OC)NC9=CC=CC=C39)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10094","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

methyl 15-ethylidene-10-[(15e)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl 15-ethylidene-10-[(15e)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

methyl 13-ethylidene-4-[13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-17-yl]-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

methyl 13-ethylidene-4-[13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-17-yl]-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2(7),3,5-triene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

(2r,11s)-5,14-bis[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-19,24-dimethyl-3,12,21,24-tetraazahexacyclo[9.7.3.3²,¹⁰.0¹,¹⁰.0⁴,⁹.0¹³,¹⁸]tetracosa-4(9),5,7,13(18),14,16-hexaene

(2r,11s)-5,14-bis[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-19,24-dimethyl-3,12,21,24-tetraazahexacyclo[9.7.3.3²,¹⁰.0¹,¹⁰.0⁴,⁹.0¹³,¹⁸]tetracosa-4(9),5,7,13(18),14,16-hexaene

C44H50N8 (690.4158219999999)


   

(3as,8as)-7-[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-3a-[(3ar,8ar)-7-[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indole

(3as,8as)-7-[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-3a-[(3ar,8ar)-7-[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indole

C44H50N8 (690.4158219999999)


   

21,24-dimethyl-5,14-bis({1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl})-3,12,21,24-tetraazahexacyclo[9.7.3.3²,¹⁰.0¹,¹⁰.0⁴,⁹.0¹³,¹⁸]tetracosa-4,6,8,13(18),14,16-hexaene

21,24-dimethyl-5,14-bis({1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl})-3,12,21,24-tetraazahexacyclo[9.7.3.3²,¹⁰.0¹,¹⁰.0⁴,⁹.0¹³,¹⁸]tetracosa-4,6,8,13(18),14,16-hexaene

C44H50N8 (690.4158219999999)


   

(2s,3r,4s,5r,6r)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl (1s,4r,5r,9r,10r,12r,13r)-12-(acetyloxy)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-5-carboxylate

(2s,3r,4s,5r,6r)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl (1s,4r,5r,9r,10r,12r,13r)-12-(acetyloxy)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-5-carboxylate

C36H50O13 (690.3251250000001)


   

methyl (1r,9r,10s,12s,13e,16s,17r,18s)-13-ethylidene-18-hydroxy-8-{[(1r,12r,13r,16r,17r,18r)-16-hydroxy-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8-tetraen-17-yl]methyl}-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2,4,6-triene-17-carboxylate

methyl (1r,9r,10s,12s,13e,16s,17r,18s)-13-ethylidene-18-hydroxy-8-{[(1r,12r,13r,16r,17r,18r)-16-hydroxy-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8-tetraen-17-yl]methyl}-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2,4,6-triene-17-carboxylate

C42H50N4O5 (690.3781009999999)


   

methyl (9r,12s,13z,16s,17r,18s)-13-ethylidene-18-hydroxy-8-{[(1s,12s,13r,16r,17r,18r)-16-hydroxy-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8-tetraen-17-yl]methyl}-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2,4,6-triene-17-carboxylate

methyl (9r,12s,13z,16s,17r,18s)-13-ethylidene-18-hydroxy-8-{[(1s,12s,13r,16r,17r,18r)-16-hydroxy-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8-tetraen-17-yl]methyl}-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2,4,6-triene-17-carboxylate

C42H50N4O5 (690.3781009999999)


   

{[13-hydroxy-21-(4-hydroxy-1-methoxy-2-oxopentyl)-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl]oxy}methanimidic acid

{[13-hydroxy-21-(4-hydroxy-1-methoxy-2-oxopentyl)-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl]oxy}methanimidic acid

C35H50N2O12 (690.336358)


   

(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-phenylpropylidene]amino}-4-methylpentanoyl]-6-{[(2r,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-octahydroindole-2-carboximidic acid

(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-phenylpropylidene]amino}-4-methylpentanoyl]-6-{[(2r,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-octahydroindole-2-carboximidic acid

C34H54N6O9 (690.3952074)


   

4-{[5,7-dimethoxy-8-(3-methylbut-2-en-1-yl)-2-phenyl-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-5,7-dimethoxy-8-(3-methylbut-2-en-1-yl)-2-phenyl-3,4-dihydro-2h-1-benzopyran

4-{[5,7-dimethoxy-8-(3-methylbut-2-en-1-yl)-2-phenyl-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-5,7-dimethoxy-8-(3-methylbut-2-en-1-yl)-2-phenyl-3,4-dihydro-2h-1-benzopyran

C44H50O7 (690.3556349999999)


   

2-({4-[(5-carbamimidamido-1-hydroxy-2-{[1-hydroxy-4-(4-hydroxyphenyl)butylidene]amino}pentylidene)amino]-1,3-dihydroxy-5-phenylpentylidene}amino)-3-(4-hydroxyphenyl)propanoic acid

2-({4-[(5-carbamimidamido-1-hydroxy-2-{[1-hydroxy-4-(4-hydroxyphenyl)butylidene]amino}pentylidene)amino]-1,3-dihydroxy-5-phenylpentylidene}amino)-3-(4-hydroxyphenyl)propanoic acid

C36H46N6O8 (690.3376956000001)


   

methyl (1r,9r,10s,12s,13e,16s,17r,18r)-13-ethylidene-18-hydroxy-8-{[(1s,12s,13r,16r,17r,18r)-16-hydroxy-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8-tetraen-17-yl]methyl}-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2,4,6-triene-17-carboxylate

methyl (1r,9r,10s,12s,13e,16s,17r,18r)-13-ethylidene-18-hydroxy-8-{[(1s,12s,13r,16r,17r,18r)-16-hydroxy-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8-tetraen-17-yl]methyl}-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2,4,6-triene-17-carboxylate

C42H50N4O5 (690.3781009999999)


   

[6,16-dihydroxy-7,9,13-trimethyl-6-(3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxidanesulfonic acid

[6,16-dihydroxy-7,9,13-trimethyl-6-(3-methyl-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl)-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxidanesulfonic acid

C33H54O13S (690.3284954000001)


   

22-hydroxy-1,2,6,6,10,19-hexamethyl-16-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

22-hydroxy-1,2,6,6,10,19-hexamethyl-16-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-21-oxahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁸,²³]pentacos-14-en-8-yl acetate

C38H58O11 (690.3978918)


   

(2s,3s,4s,5r,6r)-6-{[(1r,2s,3as,3bs,5s,5as,7s,9as,11as)-2-hydroxy-1-[(2s)-2-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-5-(sulfooxy)-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

(2s,3s,4s,5r,6r)-6-{[(1r,2s,3as,3bs,5s,5as,7s,9as,11as)-2-hydroxy-1-[(2s)-2-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-5-(sulfooxy)-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C33H54O13S (690.3284954000001)


   

methyl (1s,12r,14s,15e,18s)-15-ethylidene-10-[(1s,12r,14s,15e,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,12r,14s,15e,18s)-15-ethylidene-10-[(1s,12r,14s,15e,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl 15-(acetyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl 15-(acetyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C36H50O13 (690.3251250000001)


   

2-[(2-{[2-(3-amino-2-hydroxy-n-methyldecanamido)-1-hydroxy-4-methanesulfinylbutylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

2-[(2-{[2-(3-amino-2-hydroxy-n-methyldecanamido)-1-hydroxy-4-methanesulfinylbutylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

C34H50N4O9S (690.3298330000001)


   

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s)-7,7-dimethyl-5,6-dioxooxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

(1s,3br,4r,5as,7r,9s,9as,9br,11as)-4,9-bis(acetyloxy)-1-[(3s)-7,7-dimethyl-5,6-dioxooxepan-3-yl]-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl benzoate

C41H54O9 (690.3767634000001)


   

methyl 17-ethyl-7-[15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-6-hydroxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraene-1-carboxylate

methyl 17-ethyl-7-[15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-6-hydroxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraene-1-carboxylate

C42H50N4O5 (690.3781009999999)


   

methyl (1s,12r,14s,15e,18s)-12-[(1r,15s,17s,18s)-17-acetyl-6-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-5-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,12r,14s,15e,18s)-12-[(1r,15s,17s,18s)-17-acetyl-6-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-5-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

[(1s,2s,4s,6s,7s,8r,9s,12s,13r,14r,16r)-6,16-dihydroxy-7,9,13-trimethyl-6-[(3r)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxidanesulfonic acid

[(1s,2s,4s,6s,7s,8r,9s,12s,13r,14r,16r)-6,16-dihydroxy-7,9,13-trimethyl-6-[(3r)-3-methyl-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butyl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icos-18-en-14-yl]oxidanesulfonic acid

C33H54O13S (690.3284954000001)


   

(1r,3r)-1-[(2s)-3,3-dimethyloxiran-2-yl]-3-[(1r,3r,6s,8r,12r,13r,15r,16r)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-15-yl]butyl acetate

(1r,3r)-1-[(2s)-3,3-dimethyloxiran-2-yl]-3-[(1r,3r,6s,8r,12r,13r,15r,16r)-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-15-yl]butyl acetate

C38H58O11 (690.3978918)


   

methyl (1s,12r,14s,15e,18s)-12-[(1r,17s,18s)-17-acetyl-6-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-5-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,12r,14s,15e,18s)-12-[(1r,17s,18s)-17-acetyl-6-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-5-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

9-hydroxy-6-(2-methoxypropan-2-yl)-2,9,11,14,19,19-hexamethyl-17-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[12.8.0.0²,¹¹.0⁴,¹⁰.0¹⁵,²⁰]docosa-16,20-diene-8,13,18-trione

9-hydroxy-6-(2-methoxypropan-2-yl)-2,9,11,14,19,19-hexamethyl-17-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[12.8.0.0²,¹¹.0⁴,¹⁰.0¹⁵,²⁰]docosa-16,20-diene-8,13,18-trione

C37H54O12 (690.3615084)


   

11-hydroxy-13-(2-{11-hydroxy-5,5,9-trimethyl-14,18-dioxo-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecan-13-ylidene}ethylidene)-5,5,9-trimethyl-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecane-14,18-dione

11-hydroxy-13-(2-{11-hydroxy-5,5,9-trimethyl-14,18-dioxo-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecan-13-ylidene}ethylidene)-5,5,9-trimethyl-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecane-14,18-dione

C40H50O10 (690.34038)


   

methyl (1r,9r,13e)-13-ethylidene-4-[(13e,14s,17r)-13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-17-yl]-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2,4,6-triene-18-carboxylate

methyl (1r,9r,13e)-13-ethylidene-4-[(13e,14s,17r)-13-ethylidene-18-(methoxycarbonyl)-1,11-diazapentacyclo[12.3.1.0²,⁷.0⁸,¹⁷.0¹¹,¹⁶]octadeca-2,4,6-trien-17-yl]-5-methoxy-8-methyl-8,15-diazapentacyclo[10.5.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵]octadeca-2,4,6-triene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

(2s,3s,4s,5r,6r)-6-{[(1s,3as,3br,5s,5as,7s,9ar,9bs,11as)-1-[(2s)-2-hydroxy-6-methyl-4-oxoheptan-2-yl]-9a,11a-dimethyl-5-(sulfooxy)-tetradecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

(2s,3s,4s,5r,6r)-6-{[(1s,3as,3br,5s,5as,7s,9ar,9bs,11as)-1-[(2s)-2-hydroxy-6-methyl-4-oxoheptan-2-yl]-9a,11a-dimethyl-5-(sulfooxy)-tetradecahydro-1h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C33H54O13S (690.3284954000001)


   

(2s)-2-{[(2s)-2-{[(2s)-2-[(2s,3s)-3-amino-2-hydroxy-n-methyldecanamido]-1-hydroxy-4-methanesulfinylbutylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

(2s)-2-{[(2s)-2-{[(2s)-2-[(2s,3s)-3-amino-2-hydroxy-n-methyldecanamido]-1-hydroxy-4-methanesulfinylbutylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

C34H50N4O9S (690.3298330000001)


   

1-methyl-7-{1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl}-3a-(1-methyl-3a-{1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl}-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-7-yl)-2h,3h,8h,8ah-pyrrolo[2,3-b]indole

1-methyl-7-{1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl}-3a-(1-methyl-3a-{1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl}-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-7-yl)-2h,3h,8h,8ah-pyrrolo[2,3-b]indole

C44H50N8 (690.4158219999999)


   

1-(3,3-dimethyloxiran-2-yl)-3-(13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-15-yl)butyl acetate

1-(3,3-dimethyloxiran-2-yl)-3-(13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-15-yl)butyl acetate

C38H58O11 (690.3978918)


   

{[(4e,6z,8s,9s,10e,12s,13r,14s,16r)-3,13-dihydroxy-21-[(1s,4r)-4-hydroxy-1-methoxy-2-oxopentyl]-8,14,19-trimethoxy-4,10,12,16-tetramethyl-20,22-dioxo-2-azabicyclo[16.3.1]docosa-1(21),2,4,6,10,18-hexaen-9-yl]oxy}methanimidic acid

{[(4e,6z,8s,9s,10e,12s,13r,14s,16r)-3,13-dihydroxy-21-[(1s,4r)-4-hydroxy-1-methoxy-2-oxopentyl]-8,14,19-trimethoxy-4,10,12,16-tetramethyl-20,22-dioxo-2-azabicyclo[16.3.1]docosa-1(21),2,4,6,10,18-hexaen-9-yl]oxy}methanimidic acid

C35H50N2O12 (690.336358)


   

methyl (1s,12r,14s,15z,18s)-12-[(1r,15s,17s,18r)-17-acetyl-6-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-5-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,12r,14s,15z,18s)-12-[(1r,15s,17s,18r)-17-acetyl-6-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-5-yl]-15-ethylidene-18-(hydroxymethyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

(1s,2s,4s,6r,7s,8r,9s,12s,13s,14s,15s,16s,17s,18s,19r,20s)-7,9,13-trimethyl-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6,14,15,16,17,18,19,20-octol

(1s,2s,4s,6r,7s,8r,9s,12s,13s,14s,15s,16s,17s,18s,19r,20s)-7,9,13-trimethyl-6-[3-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)but-3-en-1-yl]-5-oxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan-6,14,15,16,17,18,19,20-octol

C33H54O15 (690.3462534)


   

methyl (1s,12r,14s,15e,18s)-15-ethylidene-10-[(1s,12r,14s,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,12r,14s,15e,18s)-15-ethylidene-10-[(1s,12r,14s,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

(2s)-n-[(3z,6s,9s,12r,13r)-3-ethylidene-5,8,11-trihydroxy-9-isopropyl-6,13-dimethyl-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl]-2-{[(2r)-1-hydroxy-2-[(1-hydroxyethylidene)amino]-3-phenylpropylidene]amino}-3-phenylpropanimidic acid

(2s)-n-[(3z,6s,9s,12r,13r)-3-ethylidene-5,8,11-trihydroxy-9-isopropyl-6,13-dimethyl-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-12-yl]-2-{[(2r)-1-hydroxy-2-[(1-hydroxyethylidene)amino]-3-phenylpropylidene]amino}-3-phenylpropanimidic acid

C36H46N6O8 (690.3376956000001)


   

3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl 12-(acetyloxy)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-5-carboxylate

3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl 12-(acetyloxy)-5,9,13-trimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-5-carboxylate

C36H50O13 (690.3251250000001)


   

methyl 13-ethylidene-18-hydroxy-8-({16-hydroxy-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8-tetraen-17-yl}methyl)-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2,4,6-triene-17-carboxylate

methyl 13-ethylidene-18-hydroxy-8-({16-hydroxy-3,16,20-trimethyl-15-oxa-3,20-diazapentacyclo[10.7.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]icosa-2(10),4,6,8-tetraen-17-yl}methyl)-8,15-diazahexacyclo[14.2.1.0¹,⁹.0²,⁷.0¹⁰,¹⁵.0¹²,¹⁷]nonadeca-2,4,6-triene-17-carboxylate

C42H50N4O5 (690.3781009999999)


   

(12s,13z,16r)-11-hydroxy-13-{2-[(12s,13e,16r)-11-hydroxy-5,5,9-trimethyl-14,18-dioxo-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecan-13-ylidene]ethylidene}-5,5,9-trimethyl-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecane-14,18-dione

(12s,13z,16r)-11-hydroxy-13-{2-[(12s,13e,16r)-11-hydroxy-5,5,9-trimethyl-14,18-dioxo-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecan-13-ylidene]ethylidene}-5,5,9-trimethyl-15,17-dioxapentacyclo[9.5.2.0¹,¹⁰.0⁴,⁹.0¹²,¹⁶]octadecane-14,18-dione

C40H50O10 (690.34038)


   

(1r,2s,4r,5r,8r,9s,11r)-2-({[(2s,5r,6r,7r,9r,10r)-2-(7-carboxyheptyl)-6-hydroxy-10-methoxy-9-methyl-3-oxo-1,4,8-trioxaspiro[4.5]decan-7-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

(1r,2s,4r,5r,8r,9s,11r)-2-({[(2s,5r,6r,7r,9r,10r)-2-(7-carboxyheptyl)-6-hydroxy-10-methoxy-9-methyl-3-oxo-1,4,8-trioxaspiro[4.5]decan-7-yl]oxy}methyl)-9-formyl-13-isopropyl-5-methyltetracyclo[7.4.0.0²,¹¹.0⁴,⁸]tridec-12-ene-1-carboxylic acid

C37H54O12 (690.3615084)


   

(1s,2s,10r,11r)-5,14-bis[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-21,24-dimethyl-3,12,21,24-tetraazahexacyclo[9.7.3.3²,¹⁰.0¹,¹⁰.0⁴,⁹.0¹³,¹⁸]tetracosa-4,6,8,13(18),14,16-hexaene

(1s,2s,10r,11r)-5,14-bis[(3ar,8ar)-1-methyl-2h,3h,8h,8ah-pyrrolo[2,3-b]indol-3a-yl]-21,24-dimethyl-3,12,21,24-tetraazahexacyclo[9.7.3.3²,¹⁰.0¹,¹⁰.0⁴,⁹.0¹³,¹⁸]tetracosa-4,6,8,13(18),14,16-hexaene

C44H50N8 (690.4158219999999)


   

methyl (1s,12r,14r,15z,18r)-15-ethylidene-10-[(1s,12s,14r,15e,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,12r,14r,15z,18r)-15-ethylidene-10-[(1s,12s,14r,15e,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-12-hydroxy-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C42H50N4O5 (690.3781009999999)


   

(3r,4ar,6ar,7r,8r,10as,10br)-3-ethenyl-3,4a,7,10a-tetramethyl-7-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydro-1h-naphtho[2,1-b]pyran-8-yl (2e)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate

(3r,4ar,6ar,7r,8r,10as,10br)-3-ethenyl-3,4a,7,10a-tetramethyl-7-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydro-1h-naphtho[2,1-b]pyran-8-yl (2e)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate

C37H54O12 (690.3615084)


   

(2r,4s)-4-{[(2r,4s)-5,7-dimethoxy-8-(3-methylbut-2-en-1-yl)-2-phenyl-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-5,7-dimethoxy-8-(3-methylbut-2-en-1-yl)-2-phenyl-3,4-dihydro-2h-1-benzopyran

(2r,4s)-4-{[(2r,4s)-5,7-dimethoxy-8-(3-methylbut-2-en-1-yl)-2-phenyl-3,4-dihydro-2h-1-benzopyran-4-yl]oxy}-5,7-dimethoxy-8-(3-methylbut-2-en-1-yl)-2-phenyl-3,4-dihydro-2h-1-benzopyran

C44H50O7 (690.3556349999999)


   

methyl (1s,15s,17r,18r)-17-ethyl-7-[(1s,12s,14r,15z,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-6-hydroxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraene-1-carboxylate

methyl (1s,15s,17r,18r)-17-ethyl-7-[(1s,12s,14r,15z,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-6-hydroxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraene-1-carboxylate

C42H50N4O5 (690.3781009999999)


   

(2s)-2-{[(3s,4s)-4-{[(2r)-5-carbamimidamido-1-hydroxy-2-{[1-hydroxy-4-(4-hydroxyphenyl)butylidene]amino}pentylidene]amino}-1,3-dihydroxy-5-phenylpentylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

(2s)-2-{[(3s,4s)-4-{[(2r)-5-carbamimidamido-1-hydroxy-2-{[1-hydroxy-4-(4-hydroxyphenyl)butylidene]amino}pentylidene]amino}-1,3-dihydroxy-5-phenylpentylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

C36H46N6O8 (690.3376956000001)


   

methyl (1s,15s,17s,18s)-17-ethyl-7-[(1r,12r,15e)-15-ethylidene-18-(methoxycarbonyl)-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-6-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraene-1-carboxylate

methyl (1s,15s,17s,18s)-17-ethyl-7-[(1r,12r,15e)-15-ethylidene-18-(methoxycarbonyl)-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-6-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraene-1-carboxylate

C42H50N4O5 (690.3781009999999)


   

3-ethenyl-3,4a,7,10a-tetramethyl-7-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydro-1h-naphtho[2,1-b]pyran-8-yl 3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate

3-ethenyl-3,4a,7,10a-tetramethyl-7-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-octahydro-1h-naphtho[2,1-b]pyran-8-yl 3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoate

C37H54O12 (690.3615084)